Sunday, February 24, 2013

Fresh from ONCOFACTS

Low Grade Serous Ovarian Cancers Respond to Selumetinib
The GOG is conducting a phase II study of low grade serous ovarian cancers, which when recurrent are usually resistant to both hormonal therapy and chemotherapy. Patients with low grade serous ovarian cancer received selumetinib, an oral small molecule inhibitor of MEK 1 and 2, part of the MAP-Kinase pathway.
Of 52 patients treated with selumetinib, all had had at least one prior systemic therapy and 15% achieved a PR while 65% maintained Stable Disease. Median PFS was 11 months and two year OS was 55%.
While 14 patients had KRAS mutations and 2 had BRAF mutations, there did not appear to be any correlation between mutation status and response. A larger phase II-III clinical trial is beginning.


No comments: